Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 15, 2024 - Issue
Submit an article Journal homepage
76
Views
0
CrossRef citations to date
0
Altmetric
COMMENTARY

The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions

Dalia Kaakour1 Department of Internal Medicine, Division of Hematology and Oncology, University of California Irvine School of Medicine Chao Family Cancer Center, Orange, CA, USA
&
Misako Nagasaka1 Department of Internal Medicine, Division of Hematology and Oncology, University of California Irvine School of Medicine Chao Family Cancer Center, Orange, CA, USA;2 Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5308-615X
ORCID Icon
Pages 49-54 | Received 13 Dec 2023, Accepted 23 Mar 2024, Published online: 23 Apr 2024

References

  • Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa0810699
  • Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8:179–184. doi:10.1097/JTO.0b013e3182779d18
  • U.S. Food & Drug Administration. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. U.S. Food & Drug Administration; 2021.
  • U.S. Food & Drug Administration. FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. U.S. Food & Drug Administration; 2021.
  • Johnson & Johnson. Treatment with RYBREVANT® (amivantamab-vmjw) plus chemotherapy resulted in statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Johnson & Johnson; 2023.
  • Zhou C, Tang K-J, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039–2051. doi:10.1056/NEJMoa2306441
  • U.S. Food & Drug Administration. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. U.S. Food & Drug Administration; 2024.
  • ClinicalTrials.Gov. TAK-788 as first-line treatment versus platinum-based chemotherapy for Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 20 insertion mutations. ClinicalTrials.Gov; 2023.
  • Takeda Takeda provides update on EXKIVITY® (mobocertinib). Takeda; 2023.
  • ClinicalTrials.Gov. A study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in participants with advanced or metastatic non-small cell lung cancer characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON). ClinicalTrials.Gov; 2023.
  • Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89–97. doi:10.1016/j.cllc.2022.11.004
  • Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates. Cancer Discov. 2021;11(9):2145–2157. doi:10.1158/2159-8290.CD-21-0226
  • Jänne PA, Wang B, Cho BC, et al. EXCLAIM-2: phase 3 trial of first-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC. ESMO Asia; 2023.
  • Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761. doi:10.1001/jamaoncol.2021.4761
  • ClinicalTrials.Gov. A phase 1/2 trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1). ClinicalTrials.Gov; 2023.
  • ClinicalTrials.Gov. Assessing an oral EGFR inhibitor, DZD9008 in patients who have advanced non-small cell lung cancer with EGFR or HER2 mutation (WU-KONG1); ClinicalTrials.Gov; 2023.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.